125 related articles for article (PubMed ID: 23523357)
1. Suppression of MMQ cells by fulvestrant: possible mechanism of action and potential application for bromocriptine-resistant prolactinomas.
Bai J; Gui S; Zhang Y
J Clin Neurosci; 2013 May; 20(5):721-5. PubMed ID: 23523357
[TBL] [Abstract][Full Text] [Related]
2. The Wnt/β-catenin signaling pathway is involved in the antitumor effect of fulvestrant on rat prolactinoma MMQ cells.
Cao L; Gao H; Li P; Gui S; Zhang Y
Tumour Biol; 2014 Jun; 35(6):5121-7. PubMed ID: 24643679
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
4. Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line.
Lv H; Li C; Gui S; Sun M; Li D; Zhang Y
J Neurooncol; 2011 Apr; 102(2):237-45. PubMed ID: 20700755
[TBL] [Abstract][Full Text] [Related]
5. Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models.
Cao L; Gao H; Gui S; Bai G; Lu R; Wang F; Zhang Y
J Neurooncol; 2014 Feb; 116(3):523-31. PubMed ID: 24407733
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients.
Wang CJ; Guo DK; You TG; Shen DW; Wang C; Tang L; Wang J; Xu RH; Zhang H
Mol Med Rep; 2014 Dec; 10(6):3125-31. PubMed ID: 25270093
[TBL] [Abstract][Full Text] [Related]
7. Effects of an estrogen receptor antagonist on proliferation, prolactin secretion and growth factor expression in the MMQ pituitary prolactinoma cell line.
Leng L; Zhang Y
J Clin Neurosci; 2011 Dec; 18(12):1694-8. PubMed ID: 22015101
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
9. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
10. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
11. Effects of fulvestrant, an estrogen receptor antagonist, on MMQ cells and its mechanism.
Li C; Sun Z; Gui S; Liu F; Zhang Y
Neuro Endocrinol Lett; 2009; 30(2):268-74. PubMed ID: 19675520
[TBL] [Abstract][Full Text] [Related]
12. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
[TBL] [Abstract][Full Text] [Related]
13. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat.
Yonezawa K; Tamaki N; Kokunai T
Neurol Med Chir (Tokyo); 1997 Dec; 37(12):901-6. PubMed ID: 9465588
[TBL] [Abstract][Full Text] [Related]
14. TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models.
Zhang Y; Ma L; Dong S; Ding Q; Wang S; Wu Q; Ni P; Zhang H; Chen Y; Wu J; Wang X
Endocr Relat Cancer; 2022 Dec; 29(12):703-716. PubMed ID: 36219868
[TBL] [Abstract][Full Text] [Related]
15. MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway.
Lei C; Jing G; Jichao W; Xiaohui L; Fang Q; Hua G; Yazhou M; Zhang Y
J Clin Endocrinol Metab; 2019 Dec; 104(12):6391-6402. PubMed ID: 31162548
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas.
Geng X; Ma L; Li Z; Li Z; Li J; Li M; Wang Q; Chen Z; Sun Q
World Neurosurg; 2017 Apr; 100():407-416. PubMed ID: 28137551
[TBL] [Abstract][Full Text] [Related]
17. ESR1 and its antagonist fulvestrant in pituitary adenomas.
Gao H; Xue Y; Cao L; Liu Q; Liu C; Shan X; Wang H; Gu Y; Zhang Y
Mol Cell Endocrinol; 2017 Mar; 443():32-41. PubMed ID: 28043824
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional imaging of hormone-secreting cells and their microvessel environment in estrogen-induced prolactinoma of the rat pituitary gland by confocal laser scanning microscopy.
Itoh J; Kawai K; Serizawa A; Yamamoto Y; Ogawa K; Matsuno A; Watanabe K; Osamura RY
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):364-70. PubMed ID: 11759065
[TBL] [Abstract][Full Text] [Related]
19. Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender.
Lv H; Li C; Gui S; Zhang Y
J Endocrinol Invest; 2012 Feb; 35(2):174-80. PubMed ID: 21422801
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression profile of bromocriptine-resistant prolactinomas.
Wu ZB; Li WQ; Lin SJ; Wang CD; Cai L; Lu JL; Chen YX; Su ZP; Shang HB; Yang WL; Zhao WG
Mol Cell Endocrinol; 2014 Sep; 395(1-2):10-8. PubMed ID: 25064468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
